Bifogade filer
Kurs & Likviditet
Kalender
2025-02-25 | Bokslutskommuniké 2024 |
2024-11-20 | Kvartalsrapport 2024-Q3 |
2024-08-27 | Kvartalsrapport 2024-Q2 |
2024-05-22 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2024-05-21 | Årsstämma |
2024-05-21 | Kvartalsrapport 2024-Q1 |
2024-02-20 | Bokslutskommuniké 2023 |
2024-02-20 | Extra Bolagsstämma 2024 |
2023-11-10 | Kvartalsrapport 2023-Q3 |
2023-08-22 | Kvartalsrapport 2023-Q2 |
2023-05-24 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2023-05-23 | Årsstämma |
2023-05-23 | Kvartalsrapport 2023-Q1 |
2023-02-15 | Bokslutskommuniké 2022 |
2022-11-16 | Kvartalsrapport 2022-Q3 |
2022-08-23 | Kvartalsrapport 2022-Q2 |
2022-05-11 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2022-05-10 | Kvartalsrapport 2022-Q1 |
2022-05-10 | Årsstämma |
2022-03-29 | Extra Bolagsstämma 2022 |
2022-02-22 | Bokslutskommuniké 2021 |
2021-11-11 | Kvartalsrapport 2021-Q3 |
2021-07-13 | Kvartalsrapport 2021-Q2 |
2021-05-20 | Split SYNT 1:10 |
2021-05-12 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2021-05-11 | Kvartalsrapport 2021-Q1 |
2021-05-11 | Årsstämma |
2021-02-18 | Bokslutskommuniké 2020 |
2020-11-12 | Kvartalsrapport 2020-Q3 |
2020-10-02 | X-dag ordinarie utdelning SYNT 1.50 SEK |
2020-07-14 | Kvartalsrapport 2020-Q2 |
2020-05-05 | Årsstämma |
2020-05-05 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-12 | Kvartalsrapport 2019-Q3 |
2019-07-14 | Kvartalsrapport 2019-Q2 |
2019-04-30 | X-dag ordinarie utdelning SYNT 1.50 SEK |
2019-04-29 | Kvartalsrapport 2019-Q1 |
2019-04-29 | Årsstämma |
2019-02-27 | Bokslutskommuniké 2018 |
2018-11-16 | Kvartalsrapport 2018-Q3 |
2018-08-22 | Kvartalsrapport 2018-Q2 |
2018-04-26 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2018-04-25 | Kvartalsrapport 2018-Q1 |
2018-04-25 | Årsstämma |
2018-02-21 | Bokslutskommuniké 2017 |
2017-11-10 | Kvartalsrapport 2017-Q3 |
2017-08-24 | Kvartalsrapport 2017-Q2 |
2017-04-26 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2017-04-25 | Årsstämma |
2017-04-25 | Kvartalsrapport 2017-Q1 |
2017-02-15 | Bokslutskommuniké 2016 |
2016-10-28 | Kvartalsrapport 2016-Q3 |
2016-08-26 | Kvartalsrapport 2016-Q2 |
2016-04-27 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2016-04-26 | Årsstämma |
2016-04-26 | Kvartalsrapport 2016-Q1 |
2016-02-26 | Bokslutskommuniké 2015 |
2015-10-30 | Kvartalsrapport 2015-Q3 |
2015-08-28 | Kvartalsrapport 2015-Q2 |
2015-04-13 | Årsstämma |
2015-04-13 | Kvartalsrapport 2015-Q1 |
2015-02-17 | X-dag ordinarie utdelning SYNT 0.00 SEK |
2015-02-13 | Bokslutskommuniké 2014 |
2014-11-28 | Kvartalsrapport 2014-Q3 |
2014-09-26 | Extra Bolagsstämma 2014 |
2014-08-29 | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
SyntheticMR announced today that their quantitative imaging software solution SyMRI[®] has received a CE-mark for its product package SyMRI MSK, which can now be marketed and sold in Europe.
The SyMRI MSK product package provides a fast scan that can help improve patient throughput, produce a range of contrast-weighted images, as well as quantitative T1, T2, and PD maps for both clinical and research practices for all MSK anatomies and joints - including spine. Quantitative imaging has shown a lot of potential within MSK applications, particularly for improved cartilage assessment.
"Europe is one of our key markets, and we look forward to introducing our MSK applications in this region," said Ulrik Harrysson, CEO, SyntheticMR. "Quantitative imaging has a clear role in MSK and spine imaging. We look forward to bringing this technology to new customer groups as well as to current users of our product package SyMRI NEURO, to help support more informed decisions and improved radiology workflows."
SyMRI uses a unique scanning sequence to measure the absolute properties of the anatomy. The product package SyMRI MSK joins SyntheticMR's growing portfolio of quantitative software solutions, which also includes SyMRI NEURO.
This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 19 January 2021.
For additional information, please contact Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87